Caplin Point Laboratories (524742) Q3 24/25 earnings summary

Executive summary

• Achieved strong, consistent growth in Q3 FY25, with nine-month FY25 revenue nearly matching or exceeding FY23 full-year levels and robust performance across all key financial metrics.

• Expansion in US and Latin America, with new product launches, own-label strategy in the US, and entry into larger markets like Mexico, Chile, Brazil, and Colombia.

• Continued investment in R&D, new product filings, and manufacturing capacity, including onco and API facilities.

• Free cash reserves at ₹1,081 Cr and total liquid assets at ₹2,042 Cr as of Dec 31, 2024, supporting ongoing projects and future acquisitions.

• Strategic shift to launching products under own label in the US for higher long-term profitability.

Financial highlights

• Q3 FY25 revenue from operations rose 15.8% YoY to ₹524.3 Cr; 9MFY25 revenue up 16.7% YoY to ₹1,505.7 Cr.

• Q3 FY25 EBITDA margin at 36.9%, PAT margin at 26.7%; 9MFY25 EBITDA margin at 36.5%, PAT margin at 26.3%.

• PAT for 9MFY25 was ₹395.8 Cr, up 16.3% YoY; PBT for 9MFY25 exceeded ₹500 Cr.

• US market revenue for 9MFY25 grew 23% YoY to ₹258 Cr; Latin America remains the largest contributor.

• Oncology business delivered ₹34 Cr turnover and turned profitable in its first full year.

Outlook and guidance

• Expect continued robust growth in US and Latin America, with new product launches, own-label strategy, and expansion into regulated markets like Canada, Australia, and Brazil.

• 10 more ANDA approvals anticipated in the next few quarters, supporting FY26 growth.

• Capex of ₹1,000+ Cr planned, with 50% nearing completion; all funded through internal accruals.

• Targeting $100 million sales in Caplin Steriles by FY27-28, with 25-30% annual growth considered achievable.

• Expansion in Mexico and Chile to drive future growth, with meaningful contributions expected in 12-24 months.